A Phase 1 Study of REM-422 in Patients With AML or Higher Risk MDS

Study Description

A Study to Evaluate the Safety and Effectiveness of REM-422 in Treating Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

Study Details

Registry ID:

NCT06297941

Conditions:

Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory

Phase:

Phase 1

Target Enrollment:

100 participants

Start Date:

April 26, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (10 sites)

• IUCT-Oncopole
  ToulouseFrance, France
• Centre Hospitalier Universitaire (CHU) de Bordeaux
  BordeauxFrance, France
• Institut de Cancerologie Gustave-Roussy
  VillejuifFrance, France
• AP-HP - Hôpital Saint-Louis
  ParisFrance, France
• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• Memorial Sloan Kettering
  New York, New YorkUnited States, United States
• Moffitt Cancer Center
  Tampa, FloridaUnited States, United States
• Mayo Clinic
  Jacksonville, FloridaUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• City of Hope
  Duarte, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →